Dr Lal PathLabs' Q2 net profit rises 6%, revenue up 18% YoY

Consolidated revenue for the said quarter came at Rs 431.9 crore, up 18 percent YoY from Rs 365.6 crore in the corresponding quarter of the previous financial year.

Diagnostic firms ride the COVID-19 wave, retention of business gains key

Diagnostic firms such as Dr Lal PathLabs, Thyrocare Technologies and Metropolis Healthcare rebound as COVID-19 related tests drive business growth. While non COVID-19 business is showing signs of normalisation, sustainability of recovery is key

Dr Lal PathLabs exposed data of millions of patients, including COVID-19 test results: Report

The data included patients’ booking details such as their name, address, phone number, email id, payment details, digital signature, and also the type of medical tests they had taken.

Hold Dr. Lal PathLabs; target of Rs 1995: Geojit

Geojit recommended recommended hold rating on Dr. Lal PathLabs with a target price of Rs 1995 in its research report dated August 06, 2020.

Sell Dr. Lal PathLabs; target of Rs 1006: Prabhudas Lilladher

Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 1006 in its research report dated August 03, 2020.

Dr Lal PathLabs Q1 profit falls 52% to Rs 28.4 crore

Its revenue was down 20.6% at Rs 266 crore against Rs 335.2 crore.

Dr Lal PathLabs shares extend gains into 3rd day; analysts positive on firm's long term story

Despite the turmoil caused by COVID-19, the stock has been gaining significantly in the calendar year 2020 so far. The stock has gained 27 percent as of July 14 close on BSE against a 13 percent fall in benchmark Sensex.

Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs

The company, in its Annual Report for 2019-20, stated that instances and situations like the COVID-19 outbreak further boost the importance of diagnostics as an integral part of healthcare system.

Sell Dr. Lal PathLabs; target of Rs 895: Prabhudas Lilladher

Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 895 in its research report dated May 19, 2020.

Thyrocare Tech, Dr Lal PathLabs rise 9% as govt allow private lab to do coronavirus testing

The total number of coronavirus cases in India rose to 147, with 10 fresh cases reported from various parts of the country.

Dr Lal PathLabs shares fall 3% despite a decent Q3 show

The company reported a 19.08 percent year-on-year increase in consolidated net profit at Rs 54.9 crore for the quarter ended December 31.

Dr Lal PathLabs Q3 net profit up 19% to Rs 54.9cr

The company had posted a net profit of Rs 46.1 crore in the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing to the BSE.

Dr Lal PathLab Standalone December 2019 Net Sales at Rs 310.40 crore, up 9.76% Y-o-Y

Dr Lal Pathlabs Q2 PAT seen up 48.8% YoY to Rs. 84.8 cr: Kotak

Net Sales are expected to increase by 14.8 percent Y-o-Y (up 8.7 percent Q-o-Q) to Rs. 364.5 crore, according to Kotak.

'Equity market selloff has boosted demand for Gold and Silver'

The overall demand for Gold and silver investments have also increased in the current period to an all-time high, due to volatile Indian equity markets and further concerns about the health of the Indian economy.

Accumulate Dr. Lal PathLabs; target of Rs 1120: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1120 in its research report dated August 14, 2019.

Dr Lal Pathlabs Q1 PAT seen up 17.6% YoY to Rs. 58.1 cr: Kotak

Net Sales are expected to increase by 14 percent Y-o-Y (up 10.7 percent Q-o-Q) to Rs. 333.2 crore, according to Kotak.

Dr. Lal PathLabs Q1 PAT seen up 5.5% YoY to Rs. 52.1 cr: Prabhudas Lilladher

Net Sales are expected to increase by 15 percent Y-o-Y (up 11.6 percent Q-o-Q) to Rs. 336.1 crore, according to Prabhudas Lilladher.

Dr Lal PathLab Standalone March 2019 Net Sales at Rs 292.00 crore, up 12.96% Y-o-Y

Dr Lal Pathlabs Q4 PAT seen up 28.3% YoY to Rs. 51.4 cr: Kotak

Net Sales are expected to increase by 15.3 percent Y-o-Y (up 5.2 percent Q-o-Q) to Rs. 307.7 crore, according to Kotak.

Dr. Lal Pathlabs Q4 PAT seen up 26.2% YoY to Rs. 50.6 cr: Prabhudas Lilladher

Net Sales are expected to increase by 30.2 percent Y-o-Y (up 18.8 percent Q-o-Q) to Rs. 347.4 crore, according to Prabhudas Lilladher.

75 BSE 500 cos can pay Rs 1.1 lakh crore more to shareholders: Report

The 75 companies can return a median of 49 percent of their total cash and cash equivalents to their shareholders.

Dr Lal PathLabs gains 3% on acquisition of Bawankar Pathology

At 1015 hrs, Dr Lal PathLabs was quoting Rs 1076, up 2.81 percent on the BSE.

Accumulate Dr. Lal PathLabs; target of Rs 1070: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1070 in its research report dated February 11, 2019.

Dr Lal PathLab Standalone December 2018 Net Sales at Rs 282.80 crore, up 11.16% Y-o-Y